2024
A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS‐102 in irinotecan‐refractory metastatic colorectal cancer patients
Lee V, Parkinson R, Zahurak M, Cope L, Cercek A, Verheul H, Gootjes E, Lenz H, Iqbal S, Jones P, Baylin S, Rami V, Ahuja N, Khoueiry A, Azad N. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS‐102 in irinotecan‐refractory metastatic colorectal cancer patients. International Journal Of Cancer 2024, 154: 1794-1801. PMID: 38312102, DOI: 10.1002/ijc.34845.Peer-Reviewed Original ResearchRefractory to irinotecanArm ATAS-102DNA methyltransferase inhibitorArm BRates of progression free survivalB. Median overall survivalEvidence of target modulationMetastatic colorectal cancer patientsResistant to systemic therapyTreatment related adverse eventsProgression free survivalPhase II studyPhase II trialKaplan-Meier ratesRelated adverse eventsColorectal cancer patientsFree survivalOverall survivalSystemic therapyAdverse eventsIrinotecanRegorafenibCancer patientsGuadecitabine
2019
Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer.
Murphy A, Walker R, Lutz E, Parkinson R, Ahuja N, Zheng L, Jaffee E, Azad N. Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer. Journal Of Clinical Oncology 2019, 37: 591-591. DOI: 10.1200/jco.2019.37.4_suppl.591.Peer-Reviewed Original ResearchArm BArm AColorectal cancerAdvanced CRC patientsMedian treatment cycleMMR-deficient CRCMMR-proficient tumorsLines of chemotherapyAdvanced colorectal cancerPre-treatment biopsiesPost-treatment biopsiesPredictors of responseEpigenetic therapyCTCAE v4.0CRC patientsImmune checkpointsMedian ageProficient tumorsRepeat biopsySingle institutionDisease progressionArm C.Arm CGrade 3Patients